Wells Fargo’s Takeda Pharmaceutical TAK Stock Holding History

Wells Fargo’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4M	Buy	1,150,820 +14,798	+1%	+$245K	﹤0.01%	1708
2026 Q1	$21M	Buy	1,136,022 +75,561	+7%	+$1.33M	﹤0.01%	1478
2025 Q4	$16.5M	Buy	1,060,461 +26,199	+3%	+$375K	﹤0.01%	1636
2025 Q3	$15.1M	Buy	1,034,262 +21,240	+2%	+$315K	﹤0.01%	1670
2025 Q2	$15.7M	Buy	1,013,022 +45,195	+5%	+$668K	﹤0.01%	1579
2025 Q1	$14.4M	Buy	967,827 +104,149	+12%	+$1.46M	﹤0.01%	1574
2024 Q4	$11.4M	Sell	863,678 -114,324	-12%	-$1.57M	﹤0.01%	1759
2024 Q3	$13.9M	Buy	978,002 +106,335	+12%	+$1.51M	﹤0.01%	1567
2024 Q2	$11.3M	Buy	871,667 +20,722	+2%	+$274K	﹤0.01%	1623
2024 Q1	$11.8M	Buy	850,945 +76,393	+10%	+$1.11M	﹤0.01%	1612
2023 Q4	$11.1M	Buy	774,552 +12,756	+2%	+$181K	﹤0.01%	1622
2023 Q3	$11.8M	Buy	761,796 +2,746	+0.4%	+$42.5K	﹤0.01%	1447
2023 Q2	$11.9M	Sell	759,050 -135,409	-15%	-$2.22M	﹤0.01%	1473
2023 Q1	$14.7M	Sell	894,459 -35,763	-4%	-$570K	﹤0.01%	1309
2022 Q4	$14.5M	Buy	930,222 +47,132	+5%	+$658K	﹤0.01%	1311
2022 Q3	$11.5M	Buy	883,090 +8,891	+1%	+$124K	﹤0.01%	1413
2022 Q2	$12.3M	Buy	874,199 +54,466	+7%	+$777K	﹤0.01%	1432
2022 Q1	$11.7M	Sell	819,733 -956,805	-54%	-$14M	﹤0.01%	1704
2021 Q4	$24.2M	Sell	1,776,538 -448,517	-20%	-$6.29M	0.01%	1199
2021 Q3	$36.4M	Sell	2,225,055 -43,602	-2%	-$732K	0.01%	1257
2021 Q2	$38.2M	Sell	2,268,657 -250,614	-10%	-$4.27M	0.01%	1243
2021 Q1	$46M	Buy	2,519,271 +106,576	+4%	+$1.92M	0.01%	1092
2020 Q4	$43.9M	Buy	2,412,695 +833,987	+53%	+$14.6M	0.01%	1057
2020 Q3	$28.2M	Buy	1,578,708 +333,298	+27%	+$6.07M	0.01%	1186
2020 Q2	$22.3M	Buy	1,245,410 +896,489	+257%	+$16.1M	0.01%	1298
2020 Q1	$5.3M	Buy	348,921 +79,797	+30%	+$1.45M	﹤0.01%	2188
2019 Q4	$5.31M	Sell	269,124 -11,559	-4%	-$221K	﹤0.01%	2516
2019 Q3	$4.83M	Buy	280,683 +99,099	+55%	+$1.71M	﹤0.01%	2581
2019 Q2	$3.21M	Buy	181,584 +101,140	+126%	+$1.84M	﹤0.01%	2951
2019 Q1	$1.64M	Buy	80,444 +69,076	+608%	+$1.39M	﹤0.01%	3520
2018 Q4	$191K	Buy	+11,368	New	+$192K	﹤0.01%	4940

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Wells Fargo's TAK Position: Q2 2026 in Review

Wells Fargo increased its Takeda Pharmaceutical (TAK) stake by 1.3% in Q2 2026, buying an estimated $245K and bringing the position to 1,150,820 shares worth $18.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Wells Fargo first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $46M in Q1 2021. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Wells Fargo held 1,150,820 shares of Takeda Pharmaceutical worth $18.4M as of Q2 2026.
Wells Fargo bought 14,798 Takeda Pharmaceutical shares in Q2 2026, an estimated $245K.
Takeda Pharmaceutical made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1708 holding.
Wells Fargo first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Wells Fargo's Takeda Pharmaceutical position peaked at $46M in Q1 2021.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.